CRINETICS PHARMACEUTICALS, INC. 11,441,648 Shares of Common Stock, par value $0.001 per share Underwriting AgreementCrinetics Pharmaceuticals, Inc. • September 13th, 2023 • Pharmaceutical preparations • New York
Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,441,648 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to 1,716,247 additional shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 9th, 2018 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement .
CRINETICS PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • May 3rd, 2018 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of February 9, 2018 by and among CRINETICS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto (collectively referred to hereinafter as the “Investors” and each individually as an “Investor”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2022 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Stephen F. Betz (“Executive”), and shall be effective as of May 22, 2018 (the “Effective Date”).
Employment AgreementEmployment Agreement • March 30th, 2022 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the "Agreement") is made and entered into as of September 13, 2021, by and between Jeff Knight (the "Executive") and Crinetics Pharmaceuticals, Inc, a Delaware corporation (the "Company").
CRINETICS PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Sales AgreementSales Agreement • August 13th, 2019 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC and Cantor Fitzgerald & Co. (collectively the “Agents”, and each individually an “Agent”), as follows:
CRINETICS PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENTStock Purchase Agreement • July 29th, 2021 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Stock Purchase Agreement (the “Agreement”) is made as of July 28, 2021 (the “Effective Date”), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchasers”).
CRINETICS PHARMACEUTICALS, INC. 10,000,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementCrinetics Pharmaceuticals, Inc. • October 9th, 2024 • Pharmaceutical preparations • New York
Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 10,000,000 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to 1,500,000 additional shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 1st, 2024 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February 27, 2024, by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule 1 hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
LEASE AGREEMENT BETWEEN 6262 LUSK INVESTORS LLC, a California limited liability company (LANDLORD) AND CRINETICS PHARMACEUTICALS, INC., a Delaware corporation (TENANT) February 21, 2018 10222 Barnes Canyon Road SAN DIEGO, CALIFORNIALease Agreement • May 3rd, 2018 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS LEASE AGREEMENT (this “Lease”) is made as of February 21, 2018 (“Effective Date”), by and between 6262 LUSK INVESTORS LLC, a California limited liability company (“Landlord”), and CRINETICS PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
CRINETICS PHARMACEUTICALS, INC. STOCK OPTION AGREEMENTStock Option Agreement • June 22nd, 2018 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
The Board of Directors of Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has approved a grant to , an individual (the “Optionee”), of an option (the “Option”) to purchase shares of Common Stock of the Company (the “Shares”), pursuant to the Company’s amended and restated 2015 Stock Incentive Plan (the “Plan”) and this Stock Option Agreement (the “Option Agreement”), as follows:
FIRST AMENDMENT TO LEASE (Crinetics Pharmaceuticals, Inc.)Lease • February 28th, 2024 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this "First Amendment") is made and entered into as of December 8, 2023, by and between SAN DIEGO 1 LLC, a Delaware limited liability company ("Landlord") and CRINETICS PHARMACEUTICALS, INC., a Delaware corporation ("Tenant"; collectively with Landlord, the "Parties"; and each individually, a "Party").
SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement and General Release • October 16th, 2024 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Separation Agreement and General Release (this “Agreement”) is made and entered into by and between Crinetics Pharmaceuticals, Inc. (the “Company”) and James Hassard (“Employee”) (Employee and the Company collectively, the “Parties”).
CRINETICS PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Sales AgreementSales Agreement • June 21st, 2024 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively the “Agents”, and each individually an “Agent”), as follows:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 1st, 2024 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 27, 2024, by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and shall become effective as of the Closing (as defined in the Purchase Agreement, defined below). Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.
CONSULTING AGREEMENTConsulting Agreement • October 16th, 2024 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (this “Agreement”) is made and entered into as of October 15, 2024 (the “Effective Date”) by and between Crinetics Pharmaceuticals, Inc. (the “Company”) and Jim Hassard (“Consultant”), an individual (each herein referred to individually as a “Party,” or collectively as the “Parties”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 7th, 2020 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ajay Madan (“Executive”), and shall be effective as of May 22, 2018 (the “Effective Date”).
LICENSE AGREEMENTLicense Agreement • May 12th, 2022 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is made as of February 25, 2022 (the “Effective Date”), by and between CRINETICS PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware, U.S.A. having a registered address at 10222 Barnes Canyon Road, Building 2, San Diego, CA 92121 U.S.A. (“Crinetics”), and SANWA KAGAKU KENKYUSHO CO., LTD., having a place of business at 35 Higashisotobori-cho, Higashi-ku, Nagoya, Aichi 461-8631 Japan (“SKK”). Crinetics and SKK are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
CONSULTING AGREEMENTConsulting Agreement • May 12th, 2022 • Crinetics Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (this “Agreement”) is made and entered into as of April 1, 2022 (the “Effective Date”) by and between Crinetics Pharmaceuticals, Inc. (the “Company”) and Ajay Madan (“Consultant”), an individual (each herein referred to individually as a “Party,” or collectively as the “Parties”).
